Rational design and discovery of potent PROTAC degraders of ASK1: a targeted therapy in MASH
- 6 June 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (8) , 3469-3494
Abstract
The first PROTAC degrader of ASK1, dASK1-VHL (60), was rationally designed and validated via in vitro assays and PK studies, demonstrating therapeutic efficacy in an MCD diet-induced MASH mouse model, underscoring its promise in metabolic diseases.Keywords
Funding Information
- Council of Scientific and Industrial Research, India (FTT070504)
This publication has 60 references indexed in Scilit:
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α InteractionJournal of the American Chemical Society, 2012
- The VSGB 2.0 model: A next generation energy model for high resolution protein structure modelingProteins: Structure, Function, and Bioinformatics, 2011
- Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosisHepatology, 2011
- The roles of ASK family proteins in stress responses and diseasesCell Communication and Signaling, 2009
- A Stress Signaling Pathway in Adipose Tissue Regulates Hepatic Insulin ResistanceScience, 2008
- Olmesartan Prevents Cardiovascular Injury and Hepatic Steatosis in Obesity and Diabetes, Accompanied by Apoptosis Signal Regulating Kinase-1 InhibitionHypertension, 2008
- Thioredoxin and protein kinases in redox signalingSeminars in Cancer Biology, 2006
- A hierarchical approach to all‐atom protein loop predictionProteins: Structure, Function, and Bioinformatics, 2004
- Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database ScreeningJournal of Medicinal Chemistry, 2004
- Vascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressorProceedings of the National Academy of Sciences, 2001